Pinned Tweet
The market has completely mispriced $MSLE.
Around $5.60, it’s valued at roughly $136M fully diluted, with $53M in cash.
If an oral drug provides even slight improvement in both DMD and FSHD, the upside is insane. DMD Mice models and Canine models all show large benefits for Forazapadon.
With a possible accelerated approval, I see a possible multibillion-dollar valuation. At a not unreasonable $5B valuation for a DMD/FSHD treatment, it would be roughly 37× today’s price. $6 would become $200+.
Take a look at your account and evaluate how many of your stocks have this kind of risk to reward.
BASECAMP readout in 6-8 weeks. I give it a 50% odds of showing some benefit. Lose $5 vs gain $200...I'll take that bet any day of the week.
Still my largest holding.
$MSLE, $SRPT
Just finished listening to the $MSLE call from this morning.
The biggest takeaway for me is that they're clearly working with the FDA on a potential accelerated approval pathway. I think changing the primary endpoint in BASECAMP to MRI fat fraction (FF) is a huge development and significantly increases the likelihood of a statistically significant results.
If the BASECAMP patients perform anywhere close to the TRAILHEAD group in terms of FF reduction, along with improvements in strength or other functional measures, I think they have a very good shot at accelerated approval.
One thing I found particularly interesting during the Q&A was that the TRAILHEAD patients didn't experience any meaningful weight loss despite the reduction in muscle FF. Makes me wonder if some of that fat is actually being replaced by muscle rather than just a decrease in weight. That would likely support that the drug is actually improving DMD rather than simply slowing it down.
They also discussed how the younger BASECAMP patients may show greater improvements in strength and function because they have more muscle remaining for forazapadin to work on compared to the older TRAILHEAD patients.
When I look at all the data so far, from mice to dogs to TRAILHEAD, I haven't seen anything that makes me think the drug isn't working as theorized. Obviously there are still risks, but the results continue to support the mechanism.
I still believe $MSLE is the most undervalued biotech in my portfolio. A 10-15x return at these levels is completly reasonable and it remains my largest position by far. I'm more optimistic about its prospects today than ever before.
$MSLE - Hopefully good news tomorrow with the meeting. Best guess is it's about potential acclerated approval. At least that is my hope. In this market, anything positive is welcomed with open arms. lol....
I'm still holding to my price target of $85.00 if the data comes in stat sig with even modest improvement. 🙏
1
7
398
$MSLE
All smaller and micro biotechs have been beaten down the last month between 25-50%. $MSLE has been part of this destruction.
Nothing has changed with the thesis. If anything, updates on the studies progressing have been positive.
The only caveat is it would have been nice to receive an update from @SatellosBio on Trailhead for the quarter but it was likely a non-event and I don’t think they were performing MRI updates. Likely nothing to report.
If I didn’t already max out my position, I would be adding hand over fist at these prices.
1
5
519
$MSLE Potential update on trailhead later this week?
Last quarter’s data was released on July 8th. 3 months later - October 8th - lands on Thursday. 🤷♂️
I don’t expect anything ground breaking but any small positive trends might be detectable.
2
241
$MSLE…. Investor call was decent today.
They recognize how undervalued they are in the DMD space compared to their peers. No respect yet.
Confirmed enrollment in basecamp and discussed future FSHD and additional patients in the Trailhead study all coming this quarter.
With data read outs in trailhead and basecamp, I suspect a move to $15-20 is coming in short order and culminating in a final move in December to either $60+ or down to $5. 😅
Fairly binary, but huge upside with minimal downside if you believe the drug works. I put the odds at around 50%.
Remains my largest position
$MSLE $SRPT
3
17
1,104
$MSLE One of the most interesting findings in the Trailhead study group.
In DMD, muscle fat fraction normally increases with age as healthy muscle is replaced by fat. These patients started around average of 50% fat fraction and after 5 months, all 4 patients improved rather than progressed.
Mean MRI fat fraction: 49.7% → 46.0% (-3.7 pts)
Best responders: -6.2 and -5.8 pts
Movement in the opposite direction of DMD natural history.
Tiny N of 4 but if this signal holds in the younger Basecamp group, it could be evidence of actual muscle remodeling/regeneration rather than simply preserving what’s left.
10X+ scenario ($100+) is completely possible. DMD $SRPT $MSLE
3
13
1,362
DMD treatments.
My largest biotech position is $MSLE, and see almost exclusively posts on $SRPT.
This isn’t because I think Sarepta has no value. They’ve built an impressive DMD franchise and deserve credit for getting therapies to patients. Though the benefit appears minimal.
But from a risk/reward perspective, I think the market is looking in the rearview mirror.
Why I’m bullish on $MSLE:
• A different approach. Instead of trying to replace dystrophin, SAT-3247 is designed to restore the muscle’s ability to regenerate. Every DMD patient continues losing muscle—even after gene therapy. If you can regenerate muscle, it has the potential to complement existing treatments rather than simply replace them.
• Mutation agnostic. If successful, the approach could be applicable across the vast majority of DMD patients rather than targeting only specific mutations.
• Encouraging early data. Initial human results have shown improvements in grip strength along with biomarker changes consistent with reduced muscle degeneration and fat loss. It’s still early, but the signals are encouraging.
• Asymmetric upside. $SRPT is already a multibillion-dollar company with commercial products. $MSLE has a much smaller valuation, so if its platform proves successful, the upside could be dramatically greater. 10-20X greater.
As for $SRPT, I still struggle with one issue: the pivotal EMBARK study missed its primary endpoint, even though the secondary endpoints and longer-term follow-up have been encouraging. I believe the therapy likely provides benefit, but the that benefit is still open to debate.
Of course, $MSLE is much earlier stage, so the risk of failure is substantially higher. This is not a “safe” investment.
But if SAT-3247 truly restores muscle regeneration—and the Phase 2 data validate the mechanism—I think today’s valuation could look very different in a few years.
Disclosure: $MSLE is my largest position. Not financial advice. Do your own research. You will likely come to the same conclusion.
2
9
1,276
$MSLE This slide is from the investor's presentation yesterday. After the latest release of the trailhead data....I think the upside of a unique MOA from a simple oral medication is extremely undervalued.
I'm excited to watch this move as we get closer to Q3/Q4 releases. Only a matter of time before others catch on to the thesis and the latest positive data release.
FMV at this point is probably closer to $18-20 a share IMO.
10
798
$MSLE The next two days might be your only chance at adding shares at $150M market cap. If there is any positive response noted on Wednesday’s presentation on the trailhead group, 5X+ potential.
Downside likely around 25% given this study has already been largely discounted by the masses.
1
8
417
$MSLE. Fast Track designation to SAT-3247 for the treatment of Duchenne.
I am blown away by how little Satellos Duchenne treatment is even mentioned on X.
IF…. The drug has any benefit whatsoever….10-30x isn’t out of the question with such low liquidity.
Still my largest position due to the risk to reward.
3
10
1,002
$MSLE At this valuation, the risk to reward on any upcoming data readouts for their basecamp and trailhead studies is a 5-10x. I’m adding to my position once again.
5
369
$MSLE If their presentation today is positive, like this announcement, $MSLE should rerate to at least $1B market cap and be trading $20+ in short order. Benefits starting to show in non ambulatory DMD patients and serviceable market potentially increasing significantly with FSHD. I’ll add if we open below $14. 👊
$MSLE News: Today, we announced interim clinical and biomarker data for SAT-3247 at the @MDAorg Clinical & Scientific Conference in Orlando, Florida.
Full details in our press release: tinyurl.com/3yybs7r9
#MDAConference #MDA2026 #MuscleRegeneration #Duchenne $MSCL
There's a new version of this post
2
400
$NKTR. Random thought….. if $NKTR, who is currently seeking litigation for milestones they are entitled to receive from $LLY, now has data showing the efficacy of a drug they were previously interested in…. How might you make both stations become a win for everyone?
Let the “buyout” rumors begin.
Personally. I’m holding long, and will add on Monday if it drops under $25. The shakeout from short term investors is likely over. I’ll sell at $50+.
Patience will likely payout with $NKTR
8
1,125





